Acquisition Announced
Jazz Pharmaceuticals acquisition of Actio Biosciences
US$820m consideration
Announced 10 Aug 2026
Advisers
Jazz Pharmaceuticals
Acquirer
- Financial adviser
- Legal adviser
- Target
- Actio Biosciences
- Acquirer
- Jazz Pharmaceuticals
- Target based in
- United States
- Buyer based in
- Ireland
- Sector
- Biotech
- Tags
- Biotech, Drug Development, Rare Disease
In the league tables
Similar deals
- BioCryst Pharmaceuticals acquisition of Astria Therapeutics Oct 2025 · US$700m · Biotech
- Incyte acquisition of Vega Therapeutics Jun 2026 · US$1.3bn · Biotech
- Werewolf Therapeutics and Ambros Therapeutics merger Aug 2026 · US$500m · Biotech
- Servier acquisition of Sevasemten and Edgewise muscular dystrophy business Jun 2026 · US$1.6bn · Biotech
- BioMarin Pharmaceutical acquisition of Alesta Therapeutics Aug 2026 · US$275m · Biotech
Sources
- 2026 Centerview Partners: Centerview as financial advisor to Actio Biosciences on their sale to Jazz centerviewpartners.com
- 2026 Moelis & Company: Acquisition of Actio Biosciences, Inc. moelis.com
- 10 Aug 2026 Press release (EX-99.1, exhibit), Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio sec.gov
- 10 Aug 2026 Actio Biosciences to Be Acquired by Jazz Pharmaceuticals for Up to $1.32 Billion cooley.com
- 10 Aug 2026 Press release (PR Newswire), Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio prnewswire.com



